IntraBio Inc announced today that the U.S. Food and Drug Administration has accepted its New Drug Application for IB1001, intended for treating Niemann-Pick disease Type C. The application

Amneal Pharmaceuticals, Inc. has announced that it received approval for its Abbreviated New Drug Application from the U.S. Food and Drug Administration for ciprofloxacin and dexamethasone

ULTOMIRIS® has recently obtained approval in the United States as the first and only long-acting C5 complement inhibitor for the treatment of adult patients diagnosed with anti-aquaporin-4

Molecure S.A. is a biotechnology company specializing in the development of innovative drugs for treating various incurable diseases. The company focuses on leveraging its expertise

Today, the U.S. Food and Drug Administration has approved Duvyzat, an oral medication, for treating Duchenne Muscular Dystrophy in patients aged six and above. Duvyzat is notable for being the first nonsteroidal drug

Cabaletta Bio, Inc. has recently gained Orphan Drug Designation from the U.S. Food and Drug Administration for its investigational therapy, CABA-201, aimed at treating systemic sclerosis

Puma Biotechnology, Inc., a biopharmaceutical company, has received approval from the U.S. Food and Drug Administration for its Investigational New Drug Application concerning alisertib. This allows Puma to progress with clinical trials

Takeda has recently announced that the U.S. Food and Drug Administration approved the supplemental New Drug Application for ICLUSIG®. This approval expands the usage of ICLUSIG to treat adult patients

Telix Pharmaceuticals Limited has revealed a new partnership for its QDOSE® dosimetry software platform with ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH

KeChow Pharma, a prominent pharmaceutical company specializing in developing and commercializing innovative small molecule therapeutics for cancer, has reached a significant achievement.